The maintenance of an Outperform rating suggests that Wedbush still sees Arcus Biosciences as a strong investment. However, the reduction in the price target could reflect a reassessment of the company's growth prospects or market conditions, leading to a more conservative valuation. This news is likely to be taken as a mixed signal by investors, potentially causing short-term uncertainty in the stock's price movement.